Key result
Withholding one dose of warfarin without vitamin K in children with INRs ≥5 resulted in 89% of INRs falling below 5 the next day, with no overt bleeds or thrombotic events in the following month.
Why the study?
Does withholding warfarin without vitamin K administration safely and effectively manage INRs ≥5 in children?
Cohort (n=89)
Does withholding warfarin without vitamin K administration safely and effectively manage INRs ≥5 in children?
Withholding a single dose of warfarin without vitamin K administration is a safe and effective conservative strategy for managing non-bleeding children with INRs ≥5 and ≤8.
Answers are grounded in this paper and cite their sources.
May support withholding one warfarin dose for INRs ≥5 in children; leaves open need for randomized confirmation of safety.
BACKGROUND: Increasing numbers of children are being administered warfarin therapy as thromboprophylaxis. Warfarin has a narrow therapeutic window with a target international normalised ratio (INR) of 2-3.5, called the therapeutic range. The length of time a patient's INR remains within the therapeutic range is calculated as 'time in the therapeutic range'. Risk for haemorrhage in children receiving warfarin is 0.5%/patient-year and minor bleeding 2.3%/patient-year, which increases exponentially for INRs >5.0. Practice among non-bleeding adults with INRs ≥5 and ≤9 is to withhold warfarin and allow the INR to return to the therapeutic range. Faster warfarin clearance is correlated with younger age. METHODS AND RESULTS: The study objective was to determine the safety and effectiveness of a conservative approach for management of INRs >5 in children receiving warfarin. Children receiving warfarin with INRs ≥5 had warfarin withheld followed by a next day INR without vitamin K administration. Eighty-nine children (1-16 years) participated in the study with 2353 INRs performed. Twenty-six children had INRs ≥5, 5% of the total performed, with a mean INR of 5.9. The next day repeat mean INR after withholding one dose of warfarin was 3.3 (range 1.2-6.8) with 89% of INRs falling below 5. There were no overt bleeds or symptomatic thrombotic events in the month following the INR >5. Time in the therapeutic range for children with INRs ≥5 was 68%. CONCLUSIONS: Withholding warfarin alone for management of non-bleeding INRs ≥5 and ≤8 appears to be safe and effective.
No takes yet. Share an insight, caveat, or question.
Bauman et al. (2010) conducted a cohort in Warfarin induced coagulopathy (n=89). Withholding warfarin without vitamin K was evaluated on Next day INR <5 and absence of bleeding or thrombotic events at 1 month. Withholding one dose of warfarin without vitamin K in children with INRs ≥5 resulted in 89% of INRs falling below 5 the next day, with no overt bleeds or thrombotic events in the following month.
Synapse has enriched 10 related papers. Consider them for comparative context: